News

InCarda Therapeutics Recruiting for Phase 2 Clinical Trial in PAF

InCarda Therapeutics is currently conducting a Phase 2 clinical trial (INSTANT) in patients with symptomatic paroxysmal atrial fibrillation (PAF). For more information, please refer to the clinicaltrials.gov registration link below. https://www.clinicaltrials.gov/ct2/show/NCT03539302?term=INSTANT&cond=Atrial+Fibrillation&rank=1...

InCarda at Biotech Industry Organization’s (BIO) International Conference 2019

June 3-6, 2019 - Philadelphia, PA “Addressing Unmet Need in Cardiovascular Disease” Panel At the 2019 Biotech Industry Organization’s (BIO) International Conference held in June in Philadelphia, InCarda’s CEO, Dr. Grace Colon, was a participant on a panel of distinguished experts entitled “Addressing Unmet Need in Cardiovascular...

InCarda at 2019 Stanford Biodesign New Arrhythmia Technologies Retreat

May 7, 2019 - Palo Alto, CA At the 2019 Stanford Biodesign New Arrhythmia Technologies Retreat, InCarda’s Chief Medical Officer, Dr. Luiz Belardinelli, provided an overview of the pre-clinical and clinical development for InRhythm (flecainide for inhalation). Dr. Bellardinelli explained to the audience of cardiology experts...

InCarda at Drug Delivery West

May 6-7, 2019 - San Diego, CA “A drug delivery 2.0 conference addressing the emerging needs for best routes of delivery” - Carlos Schuler, InCarda COO, CTO and Co-founder presented at the recent Drug Delivery West conference.      ...

InCarda Therapeutics Appoints Daniel G. Welch as Executive Chairman of Board of Directors

Former Chairman and CEO of InterMune Brings Extensive Development and Commercialization Experience to Support Continued Advancement of InRhythm™ for Treatment of Atrial Fibrillation SAN FRANCISCO, CA – April 3, 2019 – InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases,...

InCarda at Sachs Associates Forum

February 25, 2019 - Zurich At the Sachs Associates Forum in Zurich, InCarda’s Dr. Grace Colón presented a company update to investors where she discussed the clinical challenges of atrial fibrillation and InCarda’s novel approach to treating it called, InRhythm (oral flecainide for inhalation). Sachs Associates is...

InCarda at BIO CEO & Investor Conference

February 11, 2019 - New York, NY At the BIO CEO and Investor Conference, Dr. Grace Colón was a panelist for a discussion on “Attacking Biological Mechanisms of Aging to Extend Healthspan” where she discussed a range of topics including the correlated risks of aging to...

New Patent Issuances Strengthen InCarda Therapeutics’ Intellectual Property Portfolio Covering Novel Inhaled Cardiovascular Therapies

U.S. Patent Broadly Expands Coverage for Inhaled Treatment of Cardiovascular Disease to Include all Class I – IV Antiarrhythmic Drugs Additional U.S. Patent Provides Coverage for Combination of Arrhythmia Electronic Monitoring with Treatment Initiation; Supports Vision of Empowering Patients to Rapidly Detect and Arrest Atrial Fibrillation...

InCarda at AF Symposium

January 24, 2019 - Boston, MA At the 2019 AF Symposium held in Boston, MA, Dr. Jeremy Ruskin presented an overview InCarda’s program of inhaled flecainide for treatment of Paroxysmal Atrial Fibrillation to several hundred clinicians in the audience.  Dr. Ruskin is Founder and Director of...